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Bacillus anthracis possesses an innate resistance to the antibiotic trimethoprim due to poor binding to
dihydrofolate reductase (DHFR); currently, there are no commercial antibacterials that target this enzyme in
B. anthracis. We have previously reported a series of dihydrophthalazine-based trimethoprim derivatives that
are inhibitors for this target. In the present work, we have synthesized one compound (RAB1) displaying
favorable 50% inhibitory concentration (54 nM) and MIC (<12.8 g/ml) values. RAB1 was cocrystallized with
the B. anthracis DHFR in the space group P212121, and X-ray diffraction data were collected to a 2.3-Å
resolution. Binding of RAB1 causes a conformational change of the side chain of Arg58 and Met37 to
accommodate the dihydrophthalazine moiety. Unlike the natural substrate or trimethoprim, the dihydro-
phthalazine group provides a large hydrophobic anchor that embeds within the DHFR active site and accounts
for its selective inhibitory activity against B. anthracis.
Bacillus anthracis has emerged as a relevant pathogen in
regard to homeland security, and national stockpiles of thera-
peutics are being sought (www.bt.cdc.gov/Stockpile/). Cur-
rently available therapies are ciprofloxacin, tetracyclines, and
penicillin (35); no available dihydrofolate reductase (DHFR)
inhibitors are indicated for anthrax. This presents an ideal
situation for combating possible future events since the B.
anthracis DHFR is not currently targeted therapeutically.
Therefore, any malicious alterations to the organism would
presumably not affect this untargeted bacterial DHFR enzyme.
We sought here to utilize this target by structure-aided design
of selective inhibitors for B. anthracis DHFR.
Unlike their eukaryotic counterparts, prokaryotes cannot
absorb dietary folate and possess a de novo folate synthesis
pathway. This results in folate utilization, requiring the action
of DHFR to carry out NADPH-dependent oxidation of dihy-
drofolate (FAH2) to tetrahydrofolate. DHFR is found in both
prokaryotes and eukaryotes, and all DHFR enzymes studied
to date are targeted by the chemotherapeutic methotrexate
(MTX) (40). Selectivity can be achieved, such as targeting
plasmodial organisms with pyrimethamine (2). In addition,
some prokaryotic DHFR’s are selectively inhibited by tri-
methoprim (TMP) (13, 28, 51).
Clinical use of TMP was reported in 1962 and microbial
resistance to TMP was identified by 1968 (25). There are three
primary classes of resistance mechanisms. The first, largely
used by gram-negative bacteria, are plasmid-encoded DHFR
enzymes (34). The second, favored by gram-positive organisms,
are point mutations. For example, TMP-resistant Streptococcus
pneumoniae strains possess an Ile-to-Leu mutation at position
100 (39), while TMP-resistant Staphylococcus aureus strains
contain a Phe-to-Tyr mutation at position 98 (23). These mech-
anisms are not mutually exclusive, and many plasmid-encoded
DHFRs contain analogous point mutations, allowing escape
from TMP action, as well as increasing the total DHFR. How-
ever, these resistance-conferring mutations compromise enzy-
matic function (23, 39).
The third mechanism of TMP resistance is a poorly under-
stood intrinsic property of the chromosomally encoded DHFR
(4). This class includes the gram-positive organism B. anthracis
(6), as well as Mycobacterium species (8). One proposal is that
selectivity arises from the volume of the binding site (16, 49).
This is directly related to TMP resistance and generally corre-
lates with more favorable Km values for FAH2 (3, 12, 39, 45),
thus making it harder to displace. However, exceptions that are
TMP sensitive with a low Km for FAH2 do exist, such as
Lactobacillus casei (24). Previous work has also highlighted
single amino acid changes relative to susceptible organisms to
explain innate resistance. In particular, B. anthracis codes for
Tyr at position 102 (equivalent to S. aureus position 98). How-
ever, crystallographic evidence has shown that this residue is
distant from the active site (10). A previous crystal structure of
B. anthracis DHFR attributed TMP resistance to residue
Phe96, which is an Ile in TMP sensitive organisms, and pre-
sented modeling studies that indicated its involvement in TMP
resistance via steric mechanisms (10).
We have previously identified dihydrophthalazine TMP de-
rivative inhibitors for this target (7). Variation of the moiety
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attached to the dihydrophthalazine ring produced 50% inhib-
itory concentrations (IC50s) ranging from 46 to 600 nM (6). In
the same assay, an IC50 of 15 nM for the universal DHFR
inhibitor MTX was obtained, while that for TMP was 77 mM
(5). Among the most effective of the dihydrophthalazine-based
inhibitors is BAL17662, now referred to as RAB1, with an MIC
of 12.8 g/ml and an IC50 of 54 nM. In the present study, we
cocrystallized RAB1, (S,E)-3-(5-((2,4-diaminopyrimidin-5-yl)
methyl)-2,3-dimethoxyphenyl)-1-(1-propylphthalazin-2(1H)-
yl)prop-2-en-1-one, with B. anthracis DHFR and report the
structure to a 2.3-Å resolution. We have also obtained a crystal
structure of B. anthracis DHFR complexed with TMP, although a
crystal lattice defect, termed pseudomerohedral twinning, has
limited our interpretation of these data. These structures pro-
vide insight into the success of this compound over the parent
TMP molecule and highlight previously unappreciated areas of
the binding site that are critical for selective inhibition of this
enzyme.
(Portions of this study were presented as a poster at the
conference “Understanding and Controlling Infectious Dis-
eases: an Agenda for the 21st Century” at the Institute Pasteur,
Paris, France, on 11 to 13 November 2008.)
MATERIALS AND METHODS
Chemical synthesis of RAB1. The synthesis of RAB1 was carried out using a
Heck reaction for the coupling of compounds 2 and 3 (Fig. 1). Diaminoben-
zylpyrimidine (compound 2) was prepared from 5-iodo-3,4-dimethoxybenz-
aldehyde (compound 4) (41) by base-promoted condensation with 3-morpho-
linopropionitrile (50), followed by treatment with guanidine hydrochloride
and sodium methoxide (47) (Fig. 1). Dihydrophthalazine (compound 3) was
prepared by the addition of propylmagnesium bromide to phthalazine (com-
pound 5), followed by acylation of the addition product with acryloyl chloride
(30, 31) (Fig. 1).
The building block compounds 2 and 3 were generated on a large scale in 50
to 60% yields. The original work (30, 31) cited yields for the Heck coupling in the
15 to 30% range on gram-scale reactions. In a preliminary experiment, a yield of
nearly 40% was obtained by using (Ph3P)2PdCl2 as the catalyst and 1-ethylpiper-
idine as the base in dimethylformamide at 120°C for 24 h (Fig. 1). Detailed
chemical synthesis is given as part of the supplementary information. Synthesized
RAB1 was evaluated as previously published and has the same MIC against B.
anthracis Ames as initially reported, i.e., between 8 and 16 g/ml (7).
Protein purification and crystallization. Expression of recombinant B. anthra-
cis DHFR was achieved by using a published protocol (6). Purification proceeded
as previously described using HisTrap format immobilized metal affinity chro-
matography resin (GE Healthcare). The His tag was cleaved by using a Novagen
thrombin cleavage kit, leaving four additional nonnative C-terminal residues
(Leu, Val, Pro, and Arg). Final purification utilized a HiPrep 26/60 Sephacryl
S-100 size exclusion column. All stages of purification were monitored by sodium
dodecyl sulfate–12.5% polyacrylamide gel electrophoresis and resulted in puri-
fication of 98%. Protein concentrations were calculated based on A280 values
using ε280 of 1.22 (calculated by ExPASy [29]).
Protein samples were concentrated to 5 optical density units/ml, and a 10
molar excess of solid ligand was added to the solution, followed by gentle mixing
to aid dissolution. The protein-ligand mixture was further concentrated and
crystallization trials were initiated. The B. anthracis DHFR-RAB1 cocrystals
grew within 1 to 2 days at 22°C in a sitting-drop format from a 30-mg/ml protein
stock solution mixed 1:1 with a well solution of 12% PEG3350, 0.2 M CaCl2, 0.1
M MES [2-(N-morpholino)ethanesulfonic acid; pH 5.8], and 3% glycerol. The B.
anthracis DHFR-TMP cocrystals grew within 10 days at 22°C in a sitting-drop
format from a 42.5-mg/ml protein stock solution mixed 1:1 with a well solution
of 13% PEG3350, 0.2 M CaCl2, 0.1 M MES (pH 5.45), and 1% ethanol.
X-ray data collection, processing, and structure quality. The best X-ray dif-
fraction data were collected from single crystals that were cryoprotected with a
50:50 mixture of Paratone-N and paraffin oil and then vitrified by plunging them
into liquid nitrogen. The data were collected on a Bruker Microstar/X8 Proteum
with a Cu rotating anode (  1.54 Å) equipped with Montel multilayer optics
and operated at 45 kV and 55 mA. The crystal temperature was maintained with
an Oxford Cyrostream COBRA low temperature, self-generating nitrogen de-
vice.
X-ray data were indexed and integrated with Saint, scaled with SADABS, and
merged with XPREP (14); pertinent statistics are presented in Table 1. A
molecular replacement solution in the space group P212121 and containing eight
molecules per asymmetric unit was readily determined with Phaser through
CCP4 (15) using a published B. anthracis DHFR structure (Protein Data Bank
[PDB] ID code 2QK8) (10) as the search model (with water and MTX removed).
Initial maps using unrefined phases revealed well-defined main-chain and side-
chain electron density throughout each molecule, including the four extra C-
terminal residues remaining from tag cleavage and RAB1 molecules (see Fig. S1
in the supplemental material). Refinement was carried out with PHENIX (1) and
included restraints based on eightfold noncrystallographic symmetry. The RAB1
model was built using a SMILES string notation with the Elbow module of
PHENIX. Manual rebuilding was carried out with the program Coot (27).
Data for the TMP cocrystal were processed in space group P1 and evaluated
for correct assignment with XPREP (14), which indicated space group P121 as
the most likely. However, data could be processed equally well in space groups
P2221 or P41. In all cases twinning, with coordinates (h, -k, -l), was identified.
This defect arises from specific crystal packing contacts and makes the compu-
tational aspect of structure determination more error-prone, causing the result-
ing electron density to be less clear. In the case of RAB1 many such twinned
crystals were also obtained; however, a different crystal form (P212121) was
identified. The lowest final R factors were obtained in space group P2 with eight
molecules per asymmetric unit. Since maximum-likelihood refinement is not
available with twinning, a least-squares target was used for refinement with
PHENIX (1). The twin law “h, -k, -l” was included during refinement, which
produced a twin fraction of 0.49. Model bias was evident within one to two
macrocycles, particularly at the extended C termini (visible as in the RAB1
structure). This bias results from the detwinning procedure’s dependence on
FIG. 1. Chemical synthesis of RAB1.
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the model (26) and significantly complicated refinement efforts. Although
electron density for TMP was less clear in the maps from molecular replace-
ment, application of twinning corrections (in the absence of TMP) during
cycles of refinement produced unambiguous density (see Fig. S1 in the sup-
plemental material).
The final structure complexed with RAB1 was refined to an Rwork of 20.6%
and an Rfree of 25.0% (Table 1). A Ramachandran plot revealed 97.1% of
residues in the favored region (1,299 total residues), 99.6% in the allowed region,
and 0.4% (5 residues) in the nonfavored region of stereochemical space. Four of
these five residues are located in a strained turn at amino acids 18 and 19, while
the fifth is in a C terminus. Chain H is the most poorly defined, and loops 67 to
73 and loops 88 to 89 were removed. In addition, numerous side chains through-
out all models were truncated to alanine as a result of high mobility, resulting in
poorly defined electron density (listed in the supplemental material).
The final structure complexed with TMP was refined to an Rwork of 23.7% and
an Rfree of 30.9% (Table 1). A Ramachandran plot revealed 90.8% of residues
in the favored region (1,279 total residues), 98.4% in the allowed region, and
1.6% (21 residues) in the nonfavored region of stereochemical space. These
residues lie in poorly defined regions, including the strained turn encompassing
residues 17 to 19, Asn66, a flexible loop from residues 131 to 135, and the C
termini of each chain. For each chain, at least one residue was removed from the
loop at positions 131 to 135; the four C-terminal residues are not visible for chain
B. As for the RAB1 structure, numerous side chains were truncated to alanine
as a result of high mobility, resulting in poorly defined electron density (listed in
the supplemental material).
Calculations of binding energy for complexes of B. anthracis DHFR with
RAB1 and TMP, as well as with the superposition of RAB1 into the human
DHFR binding site, were carried out with APBS (5) using the Python molecular
viewer (http://mgltools.scripps.edu/). Coordinates and structure factors have
been deposited and given the codes 3FL8 for the complex with RAB1 and 3FL9
for the complex with TMP.
RESULTS
Structure of B. anthracis DHFR-RAB1 complex. The crystal-
lographic repeating unit contained eight complexes in the
asymmetric unit, each with a fully occupied RAB1. Despite
cocrystallization with a racemic mixture, the crystal structure of
RAB1 in the complex was found exclusively as the S-enantio-
mer (Fig. 2), which corresponds to the active enantiomer of
MTX and follows the same path as the glutamate moiety of the
p-aminobenzyl glutamate (pABG) tail (10). This selection
seems controlled by the position of Arg53, since it is hydrogen
bonded to the ligand, which then occupies the space needed to
accommodate the other enantiomer if bound in the same over-
all conformation (Fig. 3A).
The 2,4-diaminopyrimidine moiety is situated in a conserved
pocket and makes hydrogen bonds to Met6, Val7, Glu28,
Phe96, Tyr102, and Thr115, as expected (Fig. 2). These inter-
actions are similar to those observed in complexes of DHFR
with the natural substrates FAH2 (44), MTX (10), TMP (16,
38), and B. anthracis DHFR complexed with another TMP
derivative (9). The dimethoxybenzyl moiety (a trimethoxyben-
zyl in TMP) is enclosed in a hydrophobic channel composed of
residues Asn19, Asn20, Leu21, Asn47, Ala50, and Ile51 on one
side and Leu29 on the other, with Phe96 contacting the underside
(Fig. 2). The dimethoxybenzyl group is oriented to present the
methoxy substituents to the more polar, solvent-exposed top of
the binding site. The acryloyl linker region contains the only other
hydrogen bond to protein, albeit among the weakest (3.73 Å),
between the carbonyl oxygen of the linker and a terminal nitrogen
from the guanidine group of Arg53 (Fig. 2). In six of the eight
copies of the complex with RAB1, this hydrogen bond is supple-
mented by a water bridge between Arg53 and the linker carbonyl.
The dihydrophthalazine moiety is deeply embedded in a
continuation of the hydrophobic channel, surrounded by resi-
dues Leu55 and Pro56 on one side and Leu29, Gln30, Val32,
Lys33, Thr36, and Leu41 on the other and terminating with
Arg58 (Fig. 2). In particular, the face of the dihydrophthala-
zine moiety contacts the aliphatic chain of Lys33 on one side
and Leu55 on the other. Note that a critical component of this
tight steric fit is the presence of only two double bonds in the
proximal dihydropyridazine portion of the dihydrophthalazine
ring, allowing this moiety to bend from planarity (Fig. 3B). The
resulting angle ranges from 107° to 117°, depending on which
of the eight copies is analyzed (noncrystallographic restraints
were not applied to RAB1). The aliphatic portion of Arg58
delineates the end of the binding site, and it undergoes a
substantial conformational change in the binding site as a
result of RAB1 binding. The terminal guanidino group
swings away from the site by 2.3 Å and toward solvent to
allow the dihydrophthalazine moiety full access to the site
(Fig. 3C). The movement of the Arg58 side chain is only
possible with a concomitant movement of Met37 by 4.4 Å (at
the base of helix A).
The loop centered on residue 18 is under strain as evidenced
by outlying -	 angles in the Ramachandran plot, poor elec-
tron density, and increased B factors. These residues contact
NADPH (9) and shows less order in its absence. The construct
used for the current structure retains four extra C-terminal
residues after His tag cleavage (Leu, Val, Pro, and Arg) which
are visible in the electron density map. This C-terminal tail
plays an intricate role in crystal packing by inserting into a
polar pocket composed of residues Arg45, Lys46, Arg65, and
Gln100 from a neighboring molecule (see Fig. S2b in the sup-
plemental material). In addition, one calcium ion per molecule
TABLE 1. X-ray data collection and crystallographic
refinement statistics
Data collection and
refinement RAB1 TMP
a
Data collection
Space group P212121 P2
Unit cell (A˚, °) 68.2, 135.9, 168.7 67.9, 67.6, 167.0, 
  90.12
Resolution in A˚
(range)
25–2.3 (2.4–2.3)b 30–2.4 (2.5–2.4)
Rsym 0.123 (0.476) 0.088 (0.281)
I/I 16.1 (4.8) 13.1 (4.9)
Completeness (%) 97.3 (96.7) 90.1 (72.5)
Redundancy 13.7 (11.2) 4.7 (2.7)
Refinement
No. of reflections 69,571 53,699
Rwork/Rfree 0.206/0.250 0.237/0.309
No. of atoms
Protein 10,800 10,663
Ligand/ions 288 176
Water 1,521 371
B factors (A˚2)
Protein 28.9 31.1
Ligand/ions 35.7 32.3
Water 32.4 30.4
RMS deviations
Bond length (A˚) 0.007 0.004
Bond angle (°) 1.051 0.836
a TheTMP structure was refined with the (pseudomerohedral) twinning law
(h, -k, -l) and resulted in a twinning fraction of 0.49.
b Values for the highest-resolution shell are indicated in parentheses.
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was located and also bridges crystal contacts. This calcium ion
is coordinated by Asp110 (monodentate), the mainchain carbonyl
of Tyr108, three water molecules, and Gln147 (monodentate)
from a neighboring DHFR molecule (see Fig. S2c in the supple-
mental material). One of the water molecules helps stabilize the
conformation of the N terminus by forming a hydrogen bond with
the main chain carbonyl of Met1. The C-terminal interactions are
presumed responsible for the change in crystallographic space
group and increased resolution compared to a previous structure
with MTX (PDB ID code 2QK8) (10), while no conformational
changes are noted resulting from calcium binding.
Comparison of B. anthracis DHFR-RAB1 and B. anthracis
DHFR-TMP structures. As part of the present study, a struc-
ture of B. anthracis DHFR cocrystallized with TMP has also
been obtained. In this case, intermolecular contacts favored
packing in space group P2 and, unfortunately, this crystal is a
FIG. 2. The well-defined density for RAB1 highlights a fit to the binding site that is complementary in shape and composition. (A) Electron
density from refinement prior to the addition of RAB1, contoured at 1. (B) RAB1 structure and plot of intermolecular contacts: magenta,
2,4-diaminopyrimidine group; blue, dimethoxybenzyl ring; green, dihydrophthalazine moiety. The acryloyl linker is uncolored; the enantiomeric
carbon is denoted by an asterisk. Residues depicted in blue are involved in hydrogen bonds to RAB1, denoted by green dashed lines. Red hatched
semicircles indicate hydrophobic interactions. (C) B. anthracis DHFR structure with the surface indicated in gray and RAB1 surface indicated in
red. Both the N and C termini are obscured at the back of the molecule in this view.
FIG. 3. Key interactions modulate the conformation between B. anthracis DHFR and RAB1. (A) The side chain of Arg53 would sterically
interfere with binding of the opposite enantiomer; only the S-enantiomer of RAB1 can be accommodated. (B) The side chain of Leu55 conforms
to the observed bend in the dihydropyridazine ring of RAB1’s dihydrophthalazine moiety. (C) The side chains of Arg58 and Met37 undergo a
conformational change (indicated from gray to yellow) to accommodate the dihydrophthalazine moiety of RAB1.
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perfect pseudomerohedral twin (Table 1). Notwithstanding
crystallographic limitations, this structure demonstrates that B.
anthracis DHFR can bind to TMP despite the organism’s in-
nate resistance (IC50  77.2 mM), which has been demon-
strated to result from the chromosomally encoded DHFR used
in these studies (6). However, it must not bind as well as the
natural substrate, FAH2, since it is not a successful competitive
inhibitor for the enzyme (5). This is similar to the structure of
M. tuberculosis DHFR (38) complexed with TMP, indicating
that successful cocrystallization does not necessarily correlate
with productive in vivo inhibition.
Sequence alignment of TMP-sensitive and TMP-resistant
organisms highlighted position 96 as possibly involved in over-
coming TMP inhibition; sensitive organisms contain Ile, while
B. anthracis contains Phe (10). As shown in the structure, TMP
is accommodated within the B. anthracis DHFR binding site
(Fig. 4A). The closest contact between TMP and Phe96 is just
over 3 Å. When superposed with the RAB1 structure, itself a
TMP derivative, it is evident that the dimethoxybenzyl ring
shifts significantly (1.1- to 1.8-Å translation, with the diamin-
opyrimidine ring tilted 35°) to accommodate the longer li-
gand structure of RAB1. Thus, Phe96 does appear to provide
a pivot point for the ligand motion, differing from the RAB1
structure by 0.9 Å and tilting 30° (Fig. 4A). There are no
other substantial changes in the enzyme conformation when
the RAB1 and TMP structures are compared aside from
the conformational change of Arg58 and Met37 in the pres-
ence of RAB1. The binding site appears somewhat more hy-
drated when TMP is bound instead of RAB1, including a
buried water coordinated between a methoxy group of TMP
and Asn46 and a transient water in the binding site coordi-
nated with Arg58. Although Phe96 is not an impediment to
binding, it and neighboring Gly97 are under strain, as evi-
denced by movement and the unusual rotameric configuration
at Phe96. The linker region and the dihydrophthalazine moiety
of RAB1 more than double the binding surface relative to
TMP. This size increase, combined with favorable steric con-
straints and compatible hydrophobicity, significantly increases
the binding affinity and accounts for the successful inhibition of
B. anthracis with TMP-derived RAB1.
Comparison of B. anthracis DHFR-RAB1, DHFR-MTX, and
DHFR-C17 complexed structures. Prior to this structure de-
termination, there were two available B. anthracis DHFR crys-
tal structures: one complexed with MTX (9) and the other
complexed with a TMP-derived propargyl inhibitor referred to
as compound 17 (C17) (8). The binding site of DHFR enzymes
is considered to be relatively rigid (38), and this is highlighted
by the very close superposition of enzyme-bound RAB1, MTX
(10), and C17 (9) (Fig. 4). RAB1 possesses the most surface
area for interaction (690 Å2 buried versus MTX 590 Å2
buried versus C17510 Å2, calculated with LPC software [45])
and greater torsional freedom resulting from the diaminopy-
rimidine versus MTX and the diaminopteridine of FAH2, as
well as a more flexible acryloyl linker beyond the diaminopy-
rimidine versus C17’s stiff propargyl linkage. This allows RAB1
to more easily conform to the binding site. Ligand flexibility
has previously been touted as a predictor of selectivity (17).
The conformations of B. anthracis DHFR are very similar in
all determined complexes. Comparison of the RAB1 struc-
ture to these complexes gives rise to an root mean square
(RMS) deviation at the -carbon atoms ranging from 0.46 to
0.62 Å2 (9). Among the larger differences is the gain of a helix
from residues 132 to 134 connecting 
-strand F to 
-strand G
(see Fig. S2a in the supplemental material) in the RAB1 and
C17 complexes (9). In the MTX and TMP complexes,
this region is a flexible loop, causing it to maintain a random
conformation with a 2-Å2 RMS deviation from the current
structure. However, this region is distant from the binding site
and is not expected to affect enzymatic function.
While the position of the protein chains comprising the
binding sites are relatively invariant, analysis of their flexibility
through use of crystallographic B factors reveal ligand-depen-
dent stresses (where higher B factors indicate more flexibility).
The loop on one side of the site extends from residues 20 to 33,
partially encompassing helix A, and is believed to contain reg-
ulatory elements for binding in some bacterial species (19, 44).
The largest differences are seen at residues 21 to 25, with shifts
in the main chain conformation of 1 Å relative to the MTX
complex (see Fig. S3a in the supplemental material), resulting
in a narrowing of the MTX-complexed binding site. This con-
formational shift is, in part, caused by an interaction of Leu21
with the face of the dimethoxybenzyl in RAB1 and C17,
which is much weaker in MTX due to the placement of the
benzyl ring further from this residue. Another major contrib-
utor to this ordering is a crystal packing contact between Arg24
and Asn89 of a neighboring molecule in the RAB1 complex
FIG. 4. Superposition of ligands with RAB1 (gray) reveals minor shifts in Phe96 and otherwise conserved binding site architecture reflected by
the similarity of ligand conformation. (A) TMP (yellow); (B) MTX (cyan); (C) C17 (magenta).
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(see Fig. S2d in the supplemental material) and a similar con-
tact in the C17 complex between Arg24 and Glu67 of a
neighboring molecule. This culminates in an ordering of this
region for RAB1 and C17 complexes, exemplified by the
average B factors for residues 21 to 25: RAB1 is 27.5  1.4
Å2 and C17 is 22.8  2.1 Å2, while MTX is considerably
higher at 65.3 Å2 (see Fig. S3b in the supplemental material).
The other side of the binding site is composed of residues 50
to 58, and this loop is shifted outward from the site by a modest
0.5 to 0.7 Å when RAB1 is present (see Fig. S3a in the sup-
plemental material) and a more dramatic 1 Å outward when
C17 is present. Previous estimates claim this movement corre-
lates with potency (9) and, in a crude approximation, it does
appear that the binding site is more closed at this position as
affinity increases. This is centered on residues 50 to 51, which
are adjacent to the dimethoxybenzyl ring of RAB1 and the
5-methoxy group of C17. In the C17 complex, this region is
also stabilized by interaction of NADPH with helix B (residues
45 to 52). These trends are evident in B factors of 53.3  3.9
Å2 with RAB1 and 36.3 Å2 with MTX, while they are only
27.1  0.1 Å2 with C17 (see Fig. S3b in the supplemental
material). However, the lack of extensive ligand contacts with
C17 causes this conformational change to propagate to res-
idue 54, making the binding site in the presence of C17 wider
overall. It is presumed that it is precisely these ligand contacts
with RAB1 that impart larger B factors in this region as both
ligand and protein adjust to fit to one another.
Despite these differences, superposition of the RAB1-, C17-,
and MTX-complexed structures reveals a striking similarity in
ligand position (Fig. 4). It is expected that the diamino moi-
eties would occupy the same space, but the position differs
slightly for RAB1. The maximal translation is 0.5 Å seen
around the 1 position, and the ring is tilted, pivoting from the
4-amino group, by almost 20°. This positioning is due to steric
restrictions of fitting the dihydrophthalazine moiety in the
other end of the site, causing the entire ligand to shift toward
the end of the binding site occupied by the diamino ring and
thus the NADPH site. This results in a more favorable hydro-
gen bond to the Tyr102 side chain but also imposes some
possible steric constraints with the NADPH molecule. Since
this was not present in the RAB1 complex, the C17 com-
plex was superposed and clashes between the NADPH and
RAB1 were visualized. In particular, the linker between the
2,4-diaminopyrimidine ring and the dimethoxybenzyl is only
2.4 Å from the nicotinamide ring of NADPH. In addition, the
3-methoxy group is only 2.3 Å from the ribose ring of the
nicotinamide moiety. It is possible that minor adjustments of
binding positions could relieve these close proximities if both
NADPH and RAB1 were present in the same molecule. The
other structural differences in ligands at this position arise
from the presence of an additional ethyl group attached to
C17’s 2,4-diaminopyrimidine ring at position C6, which allows
C17 to more closely approach Trp23 and Leu21. Although the
identities of the small molecule structures diverge past the
2,4-diaminopyrinidine ring, they follow the same path through
the binding site. Not surprisingly, the contact residues are also
quite similar.
Among differences in the binding of these ligands, the hy-
drogen bond between the ligand and Arg53 is variable. It is
relatively weak with RAB1 (3.73 Å), is much stronger with the
carbonyl from the pABG group of MTX (2.80 Å) (10), and is
absent in C17 due to lack of a hydrogen acceptor for interac-
tion (9). Numerous differences exist due to the smaller size of
C17, such as the Lys33 side chain, which folds over and par-
tially obstructs the downstream binding pocket. Adjacent to
this is Gln30, which mirrors the pABG Glu of MTX or the
propyl group of RAB1, but has no contacts with C17, and the
rotamer is positioned away from the binding site. In addition,
C17 does not contact Pro56 or Arg53, whereas the other two
ligands do. Overall, the number of hydrogen bonds qualita-
tively follows the affinity for these ligands, with 14 hydrogen
bonds to MTX, 10 to RAB1, and 9 to C17. It is noteworthy that
the methoxy groups of RAB1 and C17 do not contribute to the
hydrogen bonding pattern of either molecule.
Some interactions are unique to RAB1 due, in part, to the
bulk of the buried dihydrophthalazine moiety. Thr36 and
Leu41 line the bottom of the site and contact the base of the
dihydrophthalazine group on opposite sides (Fig. 2). The con-
formation of Arg58 is the same in the C17 and MTX
complexes, confirming that the conformational change in the
presence of RAB1 is due to steric requirements. This is also
true at Met37, which shifts at the -carbon by 0.6Å away from
the site when RAB1 is present. Leu55 in the RAB1 complex
is found in a different rotameric configuration, which is con-
sistent with its role in the steric fit of the dihydrophthalazine
moiety of RAB1 (Fig. 3B). Of relevance to TMP resistance,
Phe96 shifts by 0.4 to 0.6 Å with RAB1 versusMTX orC17
(Fig. 4), probably to maintain favorable van der Waals inter-
actions as the conformation of the 2,4-diaminopyrimidine ring
is altered.
How is RAB1 selective against the human DHFR enzyme?
Previous studies revealed a high selectivity of RAB1 for B.
anthracis DHFR over human DHFR (IC50  54 nM versus
110,000 nM) (7). A comparison of binding sites was made using
the human DHFR structure complexed with MTX and
NADPH (PDB ID code 1U72, RMS deviation  2.05 Å) (20).
Ligands were removed, and RAB1 was placed by superposi-
tion; putative clashes were identified with the aid of the Ligand
Protein Contacts server (46).
Previous investigations have identified human Phe31, equiv-
alent to B. anthracis residue Leu29 and human residue Pro61
(inserted relative to B. anthracis), as key residues responsible
for the lack of selectivity for the human DHFR enzyme (9, 10).
In RAB1 these residues are closest to the acryloyl linker re-
gion. Human Phe31 may impose minor restrictions that are
expected to be accommodated by slight shifts in side chains
and the flexibility conferred by the acryloyl linker of RAB1.
The insertion containing hPro61 protrudes above the binding
site and is situated well above the RAB1 superposed molecule,
although it may impact the moiety at the stereocenter (see
below). However, this loop may affect the accessibility of the
site, particularly since it is opposite human Phe31. These dy-
namics of accessibility would not be discernible from available
crystal structures.
Human Phe34, equivalent to B. anthracis Val32, is found at
the base of the binding site and would prevent RAB1 from
seating as deeply within the pocket by impinging on the dihy-
drophthalazine moiety (Fig. 5A). Human Asn64, which is an
insertion relative to B. anthracis but would be found between
residues 52 and 53, collides with the stereogenic carbon and
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propyl group extension. The largest steric clash is found with
human Arg70 and the dihydrophthalazine moiety, equivalent
to B. anthracis Arg58, which undergoes a conformational
change to relieve a similar issue of close proximity (Fig. 5A).
However, the human enzyme contains an inserted loop (resi-
dues 41 to 47) that would limit the area available to human
Arg70 for this conformational change. This is likely a key
difference that significantly contributes to the observed selec-
tivity. It is unlikely that a cocrystal could be obtained between
human DHFR and RAB1 due to these steric clashes. These
results strongly suggest that the dihydrophthalazine moiety is
responsible for the selectivity of this entire class of diaminopy-
rimidine inhibitors (7).
DISCUSSION
RAB1 (previously BALB17662) contains a propyl group
with a stereogenic carbon, and this system displayed the most
favorable MIC and binding properties. Although membrane
penetration clearly has a role in the selection of the best in-
hibitor, a shorter ethyl or longer butyl group at this position did
not perform as well in IC50 measurements (96 and 170 nM,
respectively) (7). The propyl group protrudes upward from the
binding site and terminates at the transition to solvent. It is
likely that shorter chains provided slightly less surface area for
binding, while longer chains caused stress by exposure to the
solvent. However, the IC50 for RAB1 (54 nM) is still above that
of MTX (12.2 nM) (6). This is likely a result of the loss of the
polar pABG group, which provided an additional four hydro-
gen bonds. Minimal efforts have been made to incorporate
polar adducts in similar positions within the current series of
inhibitors, but such will be considered in future refinements.
The PDB (11) contains well over 100 DHFR structures from
various species, and many of these are complexes with inhibi-
tory small molecules. An attempt was made to compare the
size of these ligands with RAB1. Among the larger inhibitors
identified were two 5-[-carboxy(alkyloxy)] TMP derivatives
complexed with P. carinii (PDB ID codes 2FZH and 2FZI)
(21), as well as the inhibitor PT523, also a TMP derivative,
complexed with human DHFR (PDB ID code 1OHJ) (18)
(Fig. 5D and E). However, their molecular extensions beyond
the diaminopyrimidine are aliphatic in composition, and the
termini are capped with a polar carboxylic acid, such as is
found in MTX. Many MTX derivatives have been described
that also seem to trend toward extended aliphatic extensions,
but these compounds lack structural data for direct three-
dimensional comparison (36, 42, 43). Interestingly, some Plas-
modium and Candida structures, which are considerably dif-
ferent from the B. anthracis enzyme, contain inhibitors, as well
as a fortuitous buffer molecule (MES) in a position roughly
equivalent with the linker-dihydrophthalazine portion of
RAB1 (PDB ID code 2BLB) (37, 48) (Fig. 5F), indicating
unoccupied volume within the binding site complexed with
those inhibitors. These are all in direct contrast to the large
FIG. 5. RAB1 cannot fit in the human DHFR binding site due to steric clashes, and no other inhibitors with structural data possess the same
determinants. (A) Human DHFR (PDB ID code 1OHJ [18]) with RAB1 (van der Waals surface shown) superpositioned into the binding site.
Human residues Phe34, Asn64, and Arg70 are shown as van der Waals spheres. (B and C) Two-dimensional structures of Iclaprim (B) and AR-709
(C). (D to F) Superposition of RAB1 (gray) with 5-[-carboxy(alkyloxy)] TMP derivatives (cyan, PDB ID code 2FZH) (21) (D); PT523, also a TMP
derivative (magenta, PDB ID code 1OHJ) (18) (E); and pyrimethamine (yellow, PDB ID code 2BLB) (37) (F). A fortuitous buffer molecule (MES)
is in a position roughly equivalent with the acryloyl linker-dihydrophthalazine moiety of RAB1. This indicates unfilled binding site volume in the
presence of pyrimethamine, allowing the buffer molecule room to bind, that in turn is filled by RAB1.
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hydrophobic bulk of the dihydrophthalazine moiety that is the
basis for this series of TMP-derived inhibitors (7), which con-
fers both affinity and selectivity at the structural level. This
indicates that the DHFR binding site, in general, can accom-
modate larger inhibitory ligands than has previously been ap-
preciated.
It is striking that the conformation of the TMP-derived
RAB1 is so similar to that of MTX and yet, unlike MTX,
RAB1 does not inhibit human DHFR. The similarity of con-
formation is directly attributable to the rigidity of the DHFR
binding site (Fig. 4C). The dihydrophthalazine moiety is re-
sponsible for the lack of selectivity for the human enzyme that
is observed with this class of inhibitors (Fig. 5A) (7). Although
accommodation of RAB1 required a conformational change,
this was limited to the side chains of Arg58 and, in turn,
residue Met37, highlighting the limited plasticity of this site
(Fig. 3C). A class of P. carinii carboxyalkyloxy inhibitors iden-
tified an obstruction of Arg70 (equivalent to B. anthracis
Arg58), and cocrystallization trials failed to observe either
ligand or that end of the ligand (22), due presumably to steric
interference from the Arg side chain. However, the dihydroph-
thalazine moiety of RAB1 is capable of swinging the equivalent
Arg side chain out of the way. This is likely an effect of affinity,
where the free energy of binding is low enough (i.e., high
affinity) to offset the energetic consequence of a conformational
change and is reflected by a modest 1.5 cal/mol binding energy.
This is in contrast to the negative binding energies calculated for
complexes with TMP (5.0 cal/mol) and human DHFR with
RAB1 (9.2 cal/mol), indicating unfavorable interactions. The
lack of other significant conformational changes in B. anthracis
DHFR, while still accommodating the large hydrophobic dihy-
drophthalazine moiety, indicates the previously incomplete utili-
zation of both the depth and the breadth of the DHFR binding
site.
Development of new DHFR-specific inhibitors has been
slow, despite being a highly validated target (33). The B. an-
thracis specific dihydropterin reductase inhibitor MANIC is
reported to inhibit B. anthracis DHFR, although the IC50 is
higher than that for TMP (102 M [10] versus 77 M [6]). The
recent structure of B. anthracis DHFR complexed with C17
(9), as discussed above, highlights the vulnerability of this or-
ganism by targeting its DHFR enzyme. However, C17 and
related inhibitors are still preliminary and, as such, possess
IC50s only in the micromolar range and have poor selectivity
versus human DHFR. Both MANIC and C17 are smaller li-
gands than RAB1, again emphasizing the role of the larger
structure in providing affinity and specificity. This is apparent
compared to TMP, which does present some strain around
residue Phe96 but is still accommodated within the binding
site. It is unclear from structural work why TMP is not an
effective in vivo inhibitor of B. anthracis DHFR, although it
seems unlikely to be a simple point mutation(s). More likely,
the lack of inhibition is due to an intrinsic property of binding
site dynamics and is probably similar to the as-yet-unknown
reason behind a lack of inhibition of the human enzyme.
Arpida, a Swiss-based company, currently has at least two
DHFR inhibitors: Iclaprim in phase III trials and AR-709 in
late preclinical development (32). Iclaprim is noted to be broad
spectrum and can also target TMP-resistant organisms (Fig.
5B). They surmise from modeling studies that resistance is
overcome due to unique contacts with residues Ile50 and
Leu54 (B. anthracis Ile51 and Leu55) (32). It is of note that
both of these residues are involved in RAB1 binding (but not
TMP binding) and, in particular, that Leu55 is responsible
for the nonplanar conformation of the dihydropyridazine
within the dihydrophthalazine moiety (Fig. 3B).
The other broad spectrum Arpida inhibitor under develop-
ment, AR-709, is comparable in size to RAB1 and contains a
terminal indole moiety substituted by a carboxamide group and
a chlorine atom (Fig. 5C). Previous work sought to model the
conformation of AR-709 based on the MTX complex (10) and,
interestingly, seems to place the terminal indole along the top
of the binding pocket (see Fig. 5C) (10). In light of the present
complexed structure with RAB1, it is expected that the termi-
nal indole would embed within the site much like the dihy-
drophthalazine moiety. The carboxamide group is modeled to
protrude up and out of the site similar to the propyl group of
RAB1. However, the carboxamide is considerably larger and,
as modeled, presents a steric clash with the human DHFR
residue Pro61. Other inhibitors in the same series as RAB1
contain benzyl, cyclopentyl, and cyclohexyl rings in place of the
propyl group (7). It is likely that the binding modes would be
similar to that of AR-709, although their performance was not
as favorable as RAB1.
It is not a coincidence that larger DHFR inhibitors are being
developed since the binding site can accommodate ligands
larger than FAH2, as seen here with RAB1. This additional
bulk confers selectivity over the human enzyme and requires a
minimal conformational change within the bacterial binding
site. This approach is in contrast to previous suggestions that
inhibitors should be no larger than the natural substrate to
minimize resistance-conferring point mutations (37). Such a
strategy would not provide the selectivity needed for a success-
ful therapeutic. Future developments should follow the RAB1
backbone but also consider properties of solubility, bioavail-
ability, and spectrum of activity. In particular, testing of more
polar groups at the enantiomeric carbon will more fully explore
additional hydrogen bonding potential analogous to MTX. We
provide here the structural foundation for these explorations
and validate B. anthracis DHFR as a viable and potent anti-
bacterial target in the fight against infections.
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